Lantern Pharma, Inc. (LTRN)

Lantern Pharma's stock price has experienced fluctuations, declining by 23.7% in the 10 days leading up to February 6, 2026. In Q3 2025, the company reported a net loss of $4.2 million, but the stock rose 6.32% in pre-market trading. The company announced encouraging LP-184 Phase 1a results and established an AI Center of Excellence in India. LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas. Lake Street initiated coverage with a "Buy" recommendation, while MarketBeat indicates a consensus rating of "Hold". Short interest in Lantern Pharma increased recently, indicating decreasing investor sentiment.

There is no direct indication of demand seasonality for Lantern Pharma's products and services. However, an analysis of LTRN's seasonal stock chart over the past 5 years suggests a "Buy Date" of October 31 and a "Sell Date" of March 22, which has resulted in a geometric average return of 27.62% above the S&P 500 Total Return Index.

Lantern Pharma, Inc. is a clinical-stage oncology company utilizing AI and ML to accelerate the discovery and development of targeted cancer therapies. Their AI and ML platform, RADR®, uses over 200 billion oncology-focused data points and a library of ML algorithms. The company's pipeline includes drug candidates like LP-184, in Phase 1 trials for solid tumors; LP-300, in Phase 2 trials for non-small cell lung cancer; LP-284, in Phase 1 trials for non-Hodgkin's lymphomas; and LP-100, advancing toward clinical evaluation for metastatic castration-resistant prostate cancer. LP-184 Phase 1a clinical trial results demonstrated all primary endpoints were achieved with a 48% clinical benefit rate. LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas in January 2026 and has shown clinical activity.

Lantern Pharma is headquartered in Dallas, Texas, and has an AI Center of Excellence in Bengaluru, India. Clinical trial advancements for LP-300 have been made in Asia, including the completion of a Japanese cohort involving multiple centers in Japan.

Lantern Pharma's brand reputation appears positive, driven by clinical advancements and its AI platform. Positive clinical trial results for drug candidates and FDA Orphan Drug Designation for LP-284 have contributed to this. The development of its RADR® AI platform and collaborations with institutions further validate its platform and approach. Analyst sentiment is mixed, with some analysts maintaining "Buy" ratings.

Lantern Pharma's ownership is distributed among Institutional Investors (7.49%), Insiders (19.24%), and Public Companies and Individual Investors (73.27%). Major institutional owners include BIOS Capital Management, LP, Vanguard Group Inc., and BlackRock, Inc.